<DOC>
	<DOCNO>NCT01937715</DOCNO>
	<brief_summary>This multicenter , open label Phase 1b/2 study patient metastatic colorectal carcinoma . The Phase 1b identify dose combination PF-05212384 plus FOLFIRI . The randomized , two-arm Phase 2 portion compare efficacy safety PF-05212384 plus FOLFIRI bevacizumab plus FOLFIRI . The study population consist patient mCRC previously treat oxaliplatin-based regimen first line set progress within 6 month end adjuvant oxaliplatin-based regimen .</brief_summary>
	<brief_title>A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Advanced colorectal carcinoma . Progression prior oxaliplatincontaining regimen use 1st line set mCRC progression within 6 month end oxaliplatincontaining regimen adjuvant setting . Tumor tissue available time screen molecular profiling . Adequate performance status . Adequate glucose control , bone marrow , kidney , liver , heart function . Participation study involve investigational drug ( ) ( Phases 14 ) current study begin and/or study participation . Prior irinotecan treatment . Prior radiation pelvis abdomen metastatic locally advanced setting . History Gilbert 's syndrome . Active brain metastasis . Deep vein thrombosis precede 2 month . History interstitial lung disease . RAS ( KRAS/NRAS ) wild type mCRC previously treat antiEGFR contain regimen ( unless contraindicate consider standard practice per clinical site country guideline ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>